Please login to the form below

Not currently logged in
Email:
Password:

Anti-BCMA

This page shows the latest Anti-BCMA news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

In June, AbbVie exercised a right to acquire TeneoOne – a Teneobio affiliate – which includes adding an anti-CD3/BCMA bispecific TNB-383B candidate for the treatment of relapsed or refractory multiple ... These three affiliates are developing an

Latest news

  • Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

    Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral neuropathy in an ongoing phase 1 study. ... The company announced the pause for the MagnetisMM-3 trial, which is

  • GSK’s anti-BCMA drug leads crowded CHMP recommendations GSK’s anti-BCMA drug leads crowded CHMP recommendations

    The anti-BCMA therapy has received a positive opinion for the treatment of relapsed and refractory multiple myeloma in patients who no longer respond to treatment with an immunomodulatory agent, a ... The positive recommendation from the CHMP means that

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for multiple myeloma. ... However, on that front there are a number of rivals already developing anti-BCMA therapeutics,

  • FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

    If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a ... This includes belantamab mafodotin, which is a particularly

  • GSK files anti-BCMA drug for myeloma after second trial win GSK files anti-BCMA drug for myeloma after second trial win

    GSK reckons it has the advantage of a solid lead over the other anti-BCMA drug therapies, while GSK2857916 also sidesteps the serious and sometimes life-threatening toxicity that is associated ... and an anti-CD38 antibody – and will try to move the

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...